中重度脂溢性皮炎复发治疗和预防中伊曲康唑口服的临床价值分析

目的:探讨伊曲康唑口服在中重度脂溢性皮炎复发治疗和预防中的临床应用价值。方法:取90例中重度脂溢性皮炎患者,按照临床治疗干预方法不同随机分为观察组(抹酮康唑乳膏+伊曲康唑口服组)和对照组(单纯涂抹酮康唑乳膏组),各组45例,比较2组疗效。结果:观察组临床治愈率与复发率均明显优于对照组(88.9%vs64.4%,6.7%vs18.7%)(P<0.05);观察组面部及躯干SDASI评分均显著低于对照组(P<0.05);2组不良事件发生率相近(P>0.05)。结论:口服伊曲康唑不仅可安全有效地治愈中重度脂溢性皮炎,值得推广。

Objective: To investigate the clinical value of itraconazole in the treatment and prevention of moderate and severe seborrheic dermatitis. Methods: 90 cases of patients with moderate to severe seborrheic dermatitis, according to clinical treatment of different intervention methods were randomly divided into observation group(with Ketoconazole Cream + oral itraconazole group) and control group(simple smear Ketoconazole Cream group), 45 cases in each group, compared the efficacy of 2 groups. Results: the cure rate was significantly better than the control group and the recurrence rate of clinical observation group(88.9%vs64.4%, 6.7%vs18.7%)(P<0.05); group face and trunk SDASI scores in the observation were significantly lower than the control group(P<0.05); the 2 groups the incidence of adverse events was similar(P>0.05). Conclusion: oral itraconazole can not only effectively and safely cure moderate and severe seborrheic dermatitis, but also deserves to be popularized.